potential of sorafenib in inhibition of multi-step carcinogenesis for hepatocellular carcinoma

• Project/Area Number: 22591325
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Radiation science
• Research Institution: Hamamatsu University School of Medicine
• Principal Investigator: TAKEHARA Yasuo 浜松医科大学, 医学部附属病院, 教授 (70188217)
• Co-Investigator(Kenkyū-buntansha): FUJIE Michio 浜松医科大学, 実験実習機器センター, 技術専門員 (90397373)
• Project Period (FY): 2010 – 2012
• Project Status: Completed (Fiscal Year 2012)
• Budget Amount: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000); Fiscal Year 2012: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000); Fiscal Year 2011: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000); Fiscal Year 2010: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
• Keywords: 画像診断学 / sorafenib / 肝細胞癌 / 多段階発癌 / 多血肝細胞癌 / 腺腫様過形成 / dysplastic nodule / 細胞・組織 / 発生・分化 / バイオテクノロジー / 病理学 / 放射線

Research Abstract

The purpose of the study was to assess if per-oral administration of sorafenib can inhibit muti-step carcinogenesis for chemically induced hepatocellular carcinoma (HCC) in rat model. Contrast enhanced MRI using Gd-EOB-DTPA and immunohistochemically stainedliver specimen were performed to evaluate the induction of the hypervascular HCC. As a result, an earlier administration of the sorafenib resulted in less developments of hypervascular HCC by inhibiting vascular inductions to the dysplastic nodules.